Real World Study of Anlotinib Capsules for Adults with Advanced Medullary Thyroid Cancer

What this Trial Is About

Researchers are evaluating the use of Anlotinib capsules in patients with advanced medullary thyroid carcinoma to observe its effectiveness and safety in a broad patient population. This real-world study aims to summarize treatment experiences and outcomes for this type of thyroid cancer, focusing on patients with inoperable locally advanced or metastatic disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is classified as a phase 4 clinical trial. The study includes two groups one receiving Anlotinib capsules at a dose of 12 mg once daily for 2 weeks followed by a 1-week break, repeating every 21 days and an observational group that collects data from patients who do not receive Anlotinib or similar small-molecule antivascular inhibitors. The study will prospectively and retrospectively gather information about these patients treatment and outcomes. Participants will be monitored for up to three years, with assessments including overall response rate and progression-free survival as primary outcomes. Secondary outcomes include disease control rate, duration of response, overall survival, and adverse event rates. Patients will undergo regular evaluations of tumor lesions, organ function, and safety monitoring throughout the study period to provide comprehensive data on treatment experiences and outcomes.

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma